National Support Materials Renin-Angiotensin System Drugs Knowledge Laboratory Case Studies

To visit another floor: Press the lift button, use the HTML version, or go to the reception
.

Data focussed Commentary

Implementation Resources

Knowledge Laboratory

- Case Studies

- Quizzes

Library

Patient Decision Aids

Workshops

- <60 minute eLearning event

- Key slides

CV - Hypertension
CV - Post MI
Diabetes type 2
Heart failure
NPCi blog - cardiovascular
NPCi blog - diabetes

NICE guidance on Hypertension - CG34
NICE guidance on Chronic Heart Failure - CG5
NICE guidance on Type 2 diabetes - CG87
NICE guidance on MI: secondary prevention - CG48
NICE guidance on Chronic Kidney Disease - CG73
SIGN guideline on Chronic Heart Failure - No. 95

Please help us to improve this site by filling in our feedback form

National Support Materials

Renin-Angiotensin System Drugs - Knowledge Laboratory

Case Studies

Telmisartan^▼ licence change
Since these NPCi materials were published, telmisartan^▼ has been licensed for cardiovascular prevention (see Summary of Product Characteristics for details). To accompany this licence change, telmisartan^▼ has become a black triangle drug intensively monitored by the MHRA and CHM. This licence extension does not change any of the messages in these materials.

ACE-inhibitors and angiotensin-2 receptor antagonists (A2RA) drugs are used in a number of indications. There are case studies which discuss their use in some of these on other floors of NPCi. Click on the links below to view them

They are also used in chronic kidney disease, for which there is NICE guidance (see especially section 1.8).

Work through the case study below to test your knowledge on Renin-angiotensin system drugs. The answers given within this case study are model answers and not the only correct answer.

Terms & Conditions